Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma

Clin Nucl Med. 1996 Sep;21(9):720-5. doi: 10.1097/00003072-199609000-00010.


The past decade has seen the identification of many clinical settings in the treatment of primary brain tumors in which information from fluorodeoxyglucose positron emission tomography (FDG-PET) might be useful, if not essential, to therapeutic formulation. FDG-PET is currently used at referral centers in the management of primary brain tumors. The clinical pattern of FDG-PET use was assessed and its value compared to other information sources in clinical decision making. The clinical records of 75 glioma patients who were evaluated by FDG-PET were reviewed. The range of circumstances in which FDG-PET was employed included: pretherapeutic baseline studies for monitoring the effect of a therapy (1% of all cases), mapping of hypermetabolic regions before surgery or biopsy (2%), mapping of hypermetabolic regions before radiotherapy (2%), postsurgical evaluation for residual tumor (2%), assessment of the malignancy of a mass as a substitute for biopsy (11%), and distinguishing between radiation necrosis and recurrent tumor (87%). Other sources of information that contributed to the therapeutic management of patients included: gadolinium-enhanced MRI, contrast-CT, and clinical findings.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain / diagnostic imaging
  • Brain / radiation effects
  • Brain Neoplasms / diagnostic imaging*
  • Brain Neoplasms / therapy
  • Deoxyglucose / analogs & derivatives*
  • Diagnosis, Differential
  • Fluorine Radioisotopes*
  • Fluorodeoxyglucose F18
  • Glioma / diagnostic imaging*
  • Glioma / therapy
  • Humans
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Radiation Injuries / diagnostic imaging
  • Retrospective Studies
  • Tomography, Emission-Computed*


  • Fluorine Radioisotopes
  • Fluorodeoxyglucose F18
  • Deoxyglucose